CNS Pharmaceuticals, Inc. (CNSP)

NASDAQ: CNSP · IEX Real-Time Price · USD
0.251
-0.007 (-2.68%)
At close: Feb 26, 2024, 4:00 PM
0.252
+0.001 (0.40%)
After-hours: Feb 26, 2024, 7:17 PM EST
-2.68%
Market Cap 2.26M
Revenue (ttm) n/a
Net Income (ttm) -18.98M
Shares Out 8.43M
EPS (ttm) -8.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 135,480
Open 0.263
Previous Close 0.258
Day's Range 0.250 - 0.269
52-Week Range 0.229 - 4.400
Beta 1.00
Analysts n/a
Price Target n/a
Earnings Date Apr 1, 2024

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharma... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol CNSP
Full Company Profile

Financial Performance

Financial Statements

News

Top 5 Health Care Stocks That Are Preparing To Pump In February

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BIOLGILDREVBZLAB
17 days ago - Benzinga

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prim...

4 weeks ago - Accesswire

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immuno...

5 weeks ago - Accesswire

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for prim...

5 weeks ago - Accesswire

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Independent DSMB recommends continuing clinical trial of Berubicin without modification Enrollment expected to be complete in early Q1 2024 HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceu...

2 months ago - Accesswire

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms of cancer that are more dea...

2 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Data presented at the Society of NeuroOncology (SNO) 28th Annual Meeting Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) ...

3 months ago - Accesswire

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months . Wi...

3 months ago - Accesswire

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023 - Topline data from preplanned interim analysis from ...

3 months ago - Accesswire

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Tuesday, October 24th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 19, 2023 / CNS Pharmaceuticals, Inc. ...

4 months ago - Accesswire

Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope

HOUSTON, TX / ACCESSWIRE / October 16, 2023 / Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure for...

4 months ago - Accesswire

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

Company on track to achieve value-driving milestones before year-end HOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical...

4 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

Completion of enrollment of study on track by end of 2023 Topline data results from interim analysis also on track to announce by end of 2023 HOUSTON, TX / ACCESSWIRE / September 7, 2023 / CNS Pharmac...

6 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutic...

6 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Data presented at the 2023 SNO/ASCO CNS Cancer Conference Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) with topline da...

7 months ago - Accesswire

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM Topline data from interim analysis fro...

7 months ago - Accesswire

CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial sites, globally Completion of enrollment of study expected by end ...

7 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference

HOUSTON, TX / ACCESSWIRE / July 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary...

7 months ago - Accesswire

CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Tuesday, July 11th at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / July 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical compan...

8 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Wednesday, June 21st at 2:30 PM ET HOUSTON, TX / ACCESSWIRE / June 14, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical compan...

9 months ago - Accesswire

CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Company continues to execute on rapid progression of enrollment toward planned interim analysis expected in the third quarter of 2023 45 clinical trial sites of the 60 sites selected across the U.S., ...

9 months ago - Accesswire

CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Enrollment in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM continues to rapidly progress toward planned interim analysis, expected in the third quarter of 2023 HOUST...

10 months ago - Accesswire

Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors

Brings over 30 years of significant biopharmaceutical industry experience and proven clinical development and operational expertise across multiple therapeutic disciplines worldwide HOUSTON, TX / ACCE...

10 months ago - Accesswire

CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC

HOUSTON, TX / ACCESSWIRE / May 3, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a...

10 months ago - Accesswire

CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study

Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("C...

10 months ago - Accesswire